Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (https://pubmed.ncbi.nlm.nih.gov/35603936/). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.

 

 

Download entire guideline document in the 2021 version: 

 

Please note: The entire guideline document was last updated in 2021 and does not contain the latest information on the individual chapters. Below you can find the individual chapters that have been successively updated in the meantime. They will be incorporated into the entire guideline document when the updating process is completed.

Download
4268

Last updated
Changes
Download
Introduction, scoping, population and targeted users
10/2021
We welcome Ivan Bogdanov, Liam Mercieca and Dimitris Rigopoulos to the group.
Download
356
Disease severity and treatment goals
10/2021
No changes
Download
607
Methods and evidence section
12/2021
Editorial changes
Download
184
Main Recommendations and Decision Grid
10/2021
Bimekuzumab was added; guselkumab and PsA was added.
Download
767
Implementation slides
10/2021
Bimekuzumab was added; guselkumab and PsA was added
Download
336
IFPA Guideline
10/2021
No changes
Download
302

Last updated
Changes
Download
Acitretin
03/2023
No changes
Download
224
Ciclosporin
03/2023
Reference added
Download
175
Fumarates
03/2023
No changes
Download
101
Methotrexate
03/2023
New data added
Download
317
Adalimumab
03/2023
No changes
Download
157
Apremilast
03/2023
New data added
Download
180
Bimekizumab
10/2021
New chapter
Download
118
Brodalumab
10/2021
Section on IBD updated
Download
81
Certolizumab – Pegol
10/2021
No changes
Download
94
Etanercept
03/2023
No changes
Download
53
Guselkumab
03/2023
No changes
Download
122
Infliximab
03/2023
No changes
Download
62
Ixekizumab
10/2021
No changes
Download
106
Risankizumab
10/2021
No changes
Download
139
Secukinumab
10/2021
No changes
Download
116
Tildrakizumab
03/2023
No changes
Download
92
Ustekinumab
03/2023
No changes
Download
87
Biosimilars
10/2021
No changes
Download
69
Newly approved medications and treatments in the pipeline
10/2021
No changes
Download
166

Last updated
Changes
Download
Psoriatic arthritis
03/2023
New data added, recommendations changed
Download
254
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Download
93
Cancer
10/2021
Editorial changes
Download
211
Depression
10/2021
No changes
Download
67
Diabetes Mellitus
10/2021
No changes
Download
127
Heart disease
03/2023
New data added
Download
106
Kidney disease
03/2023
New data added
Download
61
Neurological diseases
10/2021
New data on ixekizumab added
Download
64
Viral Hepatitis
10/2021
No / update in progress
Download
174
Tuberculosis: Screening
10/2021
Editorial changes
Download
93
Tuberculosis: Treatment
10/2021
Editorial changes
Download
112
Wish for child / Pregnancy
10/2021
Time until pregnancy added for bimekizumab
Download
211
Vaccinations
03/2023
Completely new written
Download
146
Inmunogenicity
10/2021
No changes
Download
62

Last updated
Changes
Download
Methods Report
10/2021
No changes
Download
158
Strength and limitations
10/2021
No changes
Download
60
References
10/2021
Added new references
Download
60
Abbreviations
10/2021
No changes
Download
27